Compare GraniteShares 2x Long COIN Daily ETF (CONL) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long COIN Daily ETF vs Citius Pharmaceuticals Inc — how do they compare? GraniteShares 2x Long COIN Daily ETF trades at $5.39 (market cap $510.01M), while Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M). The key difference: GraniteShares 2x Long COIN Daily ETF is far larger — about 37.4× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 21,041,836). Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long COIN Daily ETF for 15 Days and Citius Pharmaceuticals Inc for 17 Days on average.
| CONL | CTXR | |
|---|---|---|
Market Cap | $510.01M | $13.62M |
Volume | 21,041,836 | 132,438 |
Sector | Leveraged / Inverse | Health |
52-Week High | $48.58 | $1.82 |
52-Week Low | $3.93 | $0.48 |
Typical Hold Time | 15 Days | 17 Days |
Enterprise Value | — | $3.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CONL (GraniteShares 2x Long COIN Daily ETF) trades at $4.91, down 6.12% with bearish technical signals from moving averages. The ETF tracks Coinbase stock with 2x daily leverage, amplifying volatility. Recent news highlights significant price gaps and performance swings, with one article noting an 85% decline when Coinbase fell 50%. Technical indicators show oversold conditions with RSI readings below 30, suggesting potential near-term bounce.
Outlook remains highly speculative due to leveraged structure and dependency on Coinbase performance. Investment opportunity exists for tactical traders betting on Coinbase recovery, but risks include amplified losses, daily rebalancing decay, and crypto market volatility. Conservative investors should avoid due to extreme risk profile.
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About GraniteShares 2x Long COIN Daily ETF
CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
